Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 7/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5669916 | 0.91 | KCNH2 (0.41) | NPY1RLTA4H | |
| SCHEMBL5672388 | 0.83 | LTA4H (0.43) | LTA4H | |
| SCHEMBL5670000 | 0.83 | LTA4H (0.49) | NPY1RLTA4HMMP13 | |
| SCHEMBL6750841 | 0.79 | FAAH (0.39) | NPY1RLTA4H | |
| SCHEMBL6750836 | 0.79 | HRH3 (0.58) | NPY1RLTA4HNPC1RAB9AHRH3 | |
| SCHEMBL6750837 | 0.77 | GRM2 (0.45) | LTA4HGRM2MMP13NPC1RAB9A | |
| SCHEMBL5672025 | 0.76 | LTA4H (0.47) | LTA4HMMP13 | |
| SCHEMBL7327575 | 0.74 | LTA4H (0.60) | NPY1RLTA4HSMN1; SMN2HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL7355535 | 0.73 | LTA4H (0.59) | LTA4HSMN1; SMN2HTR2CHTR2BPRMT5 | |
| SCHEMBL7324858 | 0.72 | LTA4H (0.80) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1671387-A | Aryl substituted hydantoin compounds and their use as sodium channel blockers | EURO CELTIQUE SA (LU) | 2005-09-21 | — | — | CN | claimed |
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | EURO-CELTIQUE S.A. | 2004-05-20 | — | — | US | claimed |
| CN-1671387-A | Aryl substituted hydantoin compounds and their use as sodium channel blockers | EURO CELTIQUE SA (LU) | 2005-09-21 | — | — | CN | disclosed |
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | EURO-CELTIQUE S.A. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | SCN1A, CACNA1S, SCN1B | NPY1R 1069/4885LTA4H 588/4885GRM2 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.